Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Baltimore, MD

157 studies for Breast Cancer are recruiting at 414 sites within 50 miles of Baltimore, Maryland, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Baltimore.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Baltimore

Showing the 50 nearest of 157 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); Johns Hopkins University/Sidney Kimmel Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    30 sites within 50 mi
  2. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Kaiser Permanente-Woodlawn Medical Center (Baltimore, MD); Maryland Proton Treatment Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    28 sites within 50 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); Kaiser Permanente-Woodlawn Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    22 sites within 50 mi
  4. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); MedStar Franklin Square Medical Center/Weinberg Cancer Institute (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    20 sites within 50 mi
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); Sinai Hospital of Baltimore (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  6. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers

    Nearest sites: MedStar Franklin Square Medical Center/Weinberg Cancer Institute (Baltimore, MD); Mercy Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  7. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Johns Hopkins University/Sidney Kimmel Cancer Center (Baltimore, MD); Mercy Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  8. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ascension St. Agnes Hospital (Baltimore, MD); Mercy Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  9. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    NCT03053193

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Johns Hopkins Hospital (Baltimore, MD); Mercy Medical Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  10. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD); Sinai Hospital of Baltimore, Inc. (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  11. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    NCT06401421

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); MedStar Georgetown Cancer Institute (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  12. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Maryland/Greenebaum Cancer Center (Baltimore, MD); UM Upper Chesapeake Medical Center (Bel Air, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  13. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sinai Hospital of Baltimore (Baltimore, MD); University of Maryland/Greenebaum Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 50 mi
  14. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    NCT06841354

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: MedStar Franklin Square Medical Center ( Site 0031) (Baltimore, MD); MedStar Good Samaritan Hospital ( Site 0079) (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  15. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: University of Maryland/Greenebaum Cancer Center (Baltimore, MD); National Institutes of Health Clinical Center (Bethesda, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  16. Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

    NCT06500481

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Johns Hopkins University/Sidney Kimmel Cancer Center (Baltimore, MD); Sibley Memorial Hospital (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  17. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    NCT07085767

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Clinical Trial Site (Baltimore, MD); Clinical Trial Site (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  18. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greater Baltimore Medical Center (Baltimore, MD); University of Maryland/Greenebaum Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  19. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest sites: Massive Bio SYNERGY-AI site (Baltimore, MD); Massive Bio SYNERGY-AI site (Towson, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  20. GammaPod Dose Escalation Radiation for Early Stage Breast Cancer

    NCT04234386

    • Interventional
    • Ages 45 years and older
    • Sex: Female

    Nearest sites: UMMC (Baltimore, MD); Baltimore Washington Medical Center (Glen Burnie, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  21. The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

    NCT05780814

    • Interventional
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Johns Hopkins Bayview (Baltimore, MD); Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  22. QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

    NCT06551116

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: John's Hopkins Hospital (Baltimore, MD); Georgetown University - Lombardi CCC (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  23. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    NCT06312176

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Greenebaum Comprehensive Cancer Center ( Site 0036) (Baltimore, MD); Holy Cross Hospital ( Site 0073) (Silver Spring, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  24. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins (Baltimore, MD); Georgetown University Medical Center (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  25. Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

    NCT01766297

    • Phase 2
    • Ages 50 years and older
    • Sex: Female

    Nearest sites: Maryland Proton Treatment Center (Baltimore, MD); Inova Schar Cancer Institute (Fairfax, VA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    NCT05503797

    • Phase 2
    • Ages 8 years and older
    • Sex: All

    Nearest sites: The John Hopkins Hospital (Baltimore, MD); Maryland Oncology Hematology- Columbia (Rockville, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    NCT05827081

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Mercy Medical Center (Baltimore, MD); Maryland Oncology Hematology P A (Silver Spring, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  28. Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

    NCT05856773

    • Phase 3
    • Ages 19 years and older
    • Sex: Female

    Nearest sites: Maryland Proton Treatment Center (Baltimore, MD); Inova Schar Cancer Institute (Fairfax, VA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  29. PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

    NCT06245889

    • Phase 2
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  30. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    NCT06638307

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD); NEXT Virginia (Fairfax, VA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  31. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    NCT06790693

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Maryland (Baltimore, MD); Velocity Clinical Research (Annapolis, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  32. Circulating Tumor DNA

    NCT06923527

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sidney Kimmel Comprehensive Cancer Center at John Hopkins (Baltimore, MD); Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (Washington D.C., DC)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  33. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Saint Agnes Hospital, Clinical Research Center (Baltimore, MD); Maryland Oncology Hematology P.A. (Columbia, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  34. The Cancer of the Pancreas Screening-5 CAPS5)Study

    NCT02000089

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins Hospital (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

    NCT02422641

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest site: MedStar Health Research Institute (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    NCT03606967

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins University/Sidney Kimmel Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    NCT04503265

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

    NCT05029999

    • Phase 1
    • Ages 18 to 99 years
    • Sex: All

    Nearest site: Johns Hopkins University (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    NCT05123482

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. Cardiometabolic Screening Program

    NCT05386719

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

    NCT05627960

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Maryland Greenebaum Comprehensive Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    NCT05696626

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins Kimmel Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    NCT05902988

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    NCT06172478

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins University (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. Study in Patients With Breast Cancer Leptomeningeal Metastasis

    NCT06638294

    • Observational
    • Ages 18 weeks and older
    • Sex: All

    Nearest site: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

    NCT06764940

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    NCT06966700

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: Mercy Medical Center - Baltimore ( Site 0015) (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors

    NCT07032545

    • Interventional
    • Ages Any age
    • Sex: Female

    Nearest site: Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (Baltimore, MD)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.